Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 5.32
- Piotroski Score 5.00
- Grade Outperform
- Symbol (BSX)
- Company Boston Scientific Corporation
- Price $86.89
- Changes Percentage (0.52%)
- Change $0.45
- Day Low $86.11
- Day High $87.34
- Year High $88.79
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 01/28/2025
- Fiscal Year End N/A
- Average Stock Price Target $78.00
- High Stock Price Target $118.00
- Low Stock Price Target $48.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $1.19
- Trailing P/E Ratio 64.8
- Forward P/E Ratio 64.8
- P/E Growth 64.8
- Net Income $1.59 B
Income Statement
Quarterly
Annual
Latest News of BSX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Boston Scientific (BSX): A Promising Medical Stock with Strong Revenue Growth
A recent article compared Boston Scientific Corporation against other top medical stocks favored by hedge funds. The medical device industry, impacted by COVID-19, saw growth in segments like In Vitro...
By Yahoo! Finance | 4 days ago -
Beyond the Balance Sheet: What SWOT Reveals About Boston Scientific Corp (BSX)
Boston Scientific Corp faces challenges from regulatory hurdles and economic uncertainties that could impact its growth. The company's latest financial report highlights strong performance with increa...
By Yahoo! Finance | 6 days ago -
Boston Scientific Corp (BSX) Q3 2024 Earnings Call Highlights: Robust Growth and Strategic ...
The rapid adoption of FARO Pulse in AF ablations is surpassing expectations, with an anticipated market share of over 60% by 2026. Despite a trial pause, FARO Pulse's safety and efficacy are well-esta...
By Yahoo! Finance | 2 weeks ago
